TRCT
GNRX

Tower Research Capital (TRC)’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio GNRX Stock Details GNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-240
Closed -$6K – 4952
2016
Q3 		$6K Hold
240
– – ﹤0.01% 2503
2016
Q2 		$6K Sell
240
-51
-18% -$1.22K ﹤0.01% 3327
2016
Q1 		$7K Buy
+291
New +$6.98K ﹤0.01% 2475

Other funds holding GNRX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Tower Research Capital (TRC)'s GNRX Position: Q4 2016 in Review

Tower Research Capital (TRC) sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q4 2016, closing a stake of 240 shares — an estimated $6K sold.

Tower Research Capital (TRC) first reported a position in GNRX in Q1 2016 and held it in 3 quarters. The position peaked at $7K in Q1 2016. 4 funds tracked by Wall St. Rank hold GNRX as of Q4 2016.

  • Tower Research Capital (TRC) reported no remaining VanEck Vectors Generic Drugs ETF position as of Q4 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 240 VanEck Vectors Generic Drugs ETF shares in Q4 2016, an estimated $6K.
  • Tower Research Capital (TRC) first reported a position in VanEck Vectors Generic Drugs ETF in Q1 2016 and held it in 3 quarters.
  • Tower Research Capital (TRC)'s VanEck Vectors Generic Drugs ETF position peaked at $7K in Q1 2016.
  • 4 funds tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q4 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2016, filed 3 Feb 2017.